Fingolimod (FTY720) enhances hippocampal synaptic plasticity and memory in Huntington's disease by preventing p75NTR up-regulation and astrocyte-mediated inflammation

Human Molecular Genetics

Volumn 24, Issue 17, 2015, Pages 4958-4970

  Miguez, Andrés ^a,b,c   Barriga, Gerardo García Díaz ^a,b,c   Brito, Verónica ^a,b,c   Straccia, Marco ^a,b,c   Giralt, Albert ^a,b,c   Ginés, Silvia ^a,b,c   Canals, Josep M ^a,b,c   Alberch, Jordi ^a,b,c  

^a UNIVERSITY OF BARCELONA   (Spain)

^b INSTITUT D INVESTIGACIONS BIOMÈDIQUES AUGUST PI I SUNYER IDIBAPS   (Spain)

^c CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED SOBRE ENFERMEDADES NEURODEGENERATIVAS CIBERNED   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

BRAIN DERIVED NEUROTROPHIC FACTOR; BRAIN DERIVED NEUROTROPHIC FACTOR RECEPTOR; CYCLIC AMP; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; FINGOLIMOD; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INDUCIBLE NITRIC OXIDE SYNTHASE; MESSENGER RNA; NEUROTROPHIN RECEPTOR P75; POSTSYNAPTIC DENSITY PROTEIN 95; RHOA GUANINE NUCLEOTIDE BINDING PROTEIN; TUMOR NECROSIS FACTOR ALPHA; NERVE GROWTH FACTOR RECEPTOR; TNFRSF16 PROTEIN, MOUSE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASTROCYTE; ASTROCYTOSIS; CELL LOSS; CONTROLLED STUDY; DENDRITIC SPINE; DOWN REGULATION; DRUG MECHANISM; HIPPOCAMPAL CA1 REGION; HIPPOCAMPUS; HUNTINGTON CHOREA; INFLAMMATION; LONG TERM MEMORY; MALE; MEMORY DISORDER; MOUSE; NERVE CELL PLASTICITY; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; UPREGULATION; ANIMAL; DRUG EFFECTS; GENE EXPRESSION; GENETICS; MEMORY; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY;

ANIMALS; ASTROCYTES; BRAIN-DERIVED NEUROTROPHIC FACTOR; CYCLIC AMP; DENDRITIC SPINES; FINGOLIMOD HYDROCHLORIDE; GENE EXPRESSION; HIPPOCAMPUS; HUNTINGTON DISEASE; INFLAMMATION; MEMORY; MICE; NEURONAL PLASTICITY; RECEPTOR, TRKB; RECEPTORS, NERVE GROWTH FACTOR; RNA, MESSENGER; UP-REGULATION;

EID: 84941913908     PISSN: 09646906     EISSN: 14602083     Source Type: Journal    
DOI: 10.1093/hmg/ddv218     Document Type: Article

References (89)

1. Macdonald, M.E., Ambrose, C.M., Duyao, M.P., Myers, R.H., Lin, C., Srinidhi, L., Barnes, G., Taylor, S.A., James, M., Groot, N. et al. (1993) A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntingtons-disease chromosomes. Cell, 72, 971-983.
2. Lawrence, A.D., Hodges, J.R., Rosser, A.E., Kershaw, A., Ffrench-Constant, C., Rubinsztein, D.C., Robbins, T.W. and Sahakian, B.J. (1998) Evidence for specific cognitive deficits in preclinical Huntington's disease. Brain, 121, 1329-1341.
3. Lemiere, J., Decruyenaere, M., Evers-Kiebooms, G., Vandenbussche, E. and Dom, R. (2004) Cognitive changes in patients with Huntington's disease (HD) and asymptomatic carriers of the HD mutation: a longitudinal follow-up study. J. Neurol., 251, 935-942.
4. Paulsen, J.S., Langbehn, D.R., Stout, J.C., Aylward, E., Ross, C.A., Nance, M., Guttman, M., Johnson, S.,MacDonald, M., Beglinger, L.J. et al. (2008) Detection of Huntington's disease decades before diagnosis: the predict-HD study. J. Neurol. Neurosurg. Psychiatry, 79, 874-880.
5. Paulsen, J.S. (2011) Cognitive impairment in Huntington disease: diagnosis and treatment. Curr. Neurol. Neurosci. Rep., 11, 474-483.
6. Vonsattel, J.P., Myers, R.H., Stevens, T.J., Ferrante, R.J., Bird, E.D. and Richardson, E.P. (1985) Neuropathological classification of Huntington's disease. J. Neuropathol. Exp. Neurol., 44, 559-577.
7. Rosas, H.D., Liu, A.K., Hersch, S., Glessner, M., Ferrante, R.J., Salat, D.H., van der Kouwe, A., Jenkins, B.G., Dale, A.M. and Fischl, B. (2002) Regional and progressive thinning of the cortical ribbon in Huntington's disease. Neurology, 58, 695-701.
8. Rosas, H.D., Koroshetz,W.J., Chen, Y.I., Skeuse, C., Vangel, M., Cudkowicz, M.E., Caplan, K., Marek, K., Seidman, L.J., Makris, N. et al. (2003) Evidence for more widespread cerebral pathology in early HD: an MRI-based morphometric analysis. Neurology, 60, 1615-1620.
9. Van den Bogaard, S.J.A., Dumas, E.M., Ferrarini, L., Milles, J., van Buchem, M.A., van der Grond, J. and Roos, R.A.C. (2011) Shape analysis of subcortical nuclei in Huntington's disease, global versus local atrophy: results from the TRACK-HD study. J. Neurol. Sci., 307, 60-68.
10. Giralt, A., Saavedra, A., Carretón, O., Xifró, X., Alberch, J. and Pérez-navarro, E. (2011) Increased PKA signaling disrupts recognition memory and spatial memory: role in Huntington's disease. Hum. Mol. Genet., 20, 4232-4247.
11. Giralt, A., Puigdellívol, M., Carretón, O., Paoletti, P., Valero, J., Parra-damas, A., Saura, C.A., Alberch, J. and Ginés, S. (2012) Long-term memory deficits in Huntington's disease are associated with reduced CBP histone acetylase activity. Hum. Mol. Genet., 21, 1203-1216.
12. Brito,V.,Giralt,A., Enriquez-Barreto, L., Puigdellívol,M., Suelves, N., Zamora-Moratalla, A., Ballesteros, J.J., Martín, E.D., Dominguez-Iturza, N., Morales, M. et al. (2014) Neurotrophin receptor p75NTR mediates Huntington's disease-associated synaptic and memory dysfunction. J. Clin. Invest., 124, 4411-4428.
13. Park, H. and Poo, M.M. (2013) Neurotrophin regulation of neural circuit development and function. Nat. Rev. Neurosci., 14, 7-23.
14. Lee, R., Kermani, P., Teng, K.K. and Hempstead, B.L. (2001) Regulation of cell survival by secreted proneurotrophins. Science, 294, 1945-1948.
15. Canals, J.M., Pineda, J.R., Torres-Peraza, J.F., Bosch, M., Martín-Ibañez, R., Muñoz, M.T., Mengod, G., Ernfors, P. and Alberch, J. (2004) Brain-derived neurotrophic factor regulates the onset and severity of motor dysfunction associated with enkephalinergic neuronal degeneration in Huntington's disease. J. Neurosci., 24, 7727-7739.
16. Giralt, A., Rodrigo, T., Martín, E.D., Gonzalez, J.R., Milà, M., Ceña, V., Dierssen, M., Canals, J.M. and Alberch, J. (2009) Brain-derived neurotrophic factor modulates the severity of cognitive alterations induced by mutant huntingtin: involvement of phospholipaseCgamma activity and glutamate receptor expression. Neuroscience, 158, 1234-1250.
17. Zuccato, C. and Cattaneo, E. (2009) Brain-derived neurotrophic factor in neurodegenerative diseases. Nat. Rev. Neurol., 5, 311-322.
18. MacPhee, I.J. and Barker, P.A. (1997) Brain-derived neurotrophic factor binding to the p75 neurotrophin receptor reduces TrkA signaling while increasing serine phosphorylation in the TrkA intracellular domain. J. Biol. Chem., 272, 23547-23551.
19. Fayard, B., Loeffler, S., Weis, J., Vögelin, E. and Krüttgen, A. (2005) The secreted brain-derived neurotrophic factor precursor pro-BDNF binds to TrkB and p75NTR but not to TrkA or TrkC. J. Neurosci. Res., 80, 18-28.
20. Woo, N.H., Teng, H.K., Siao, C.-J., Chiaruttini, C., Pang, P.T., Milner, T.A., Hempstead, B.L. and Lu, B. (2005) Activation of p75NTR by proBDNF facilitates hippocampal long-term depression. Nat. Neurosci., 8, 1069-1077.
21. Zagrebelsky, M., Holz, A., Dechant, G., Barde, Y.-A., Bonhoeffer, T. and Korte, M. (2005) The p75 neurotrophin receptor negatively modulates dendrite complexity and spine density in hippocampal neurons. J. Neurosci., 25, 9989-9999.
22. Brito, V., Puigdellívol, M., Giralt, A., del Toro, D., Alberch, J. and Ginés, S. (2013) Imbalance of p75(NTR)/TrkB protein expression in Huntington's disease: implication for neuroprotective therapies. Cell Death Dis., 4, e595.
23. Giralt, A., Friedman, H.C., Caneda-Ferrón, B., Urbán, N., Moreno, E., Rubio, N., Blanco, J., Peterson, A., Canals, J.M. and Alberch, J. (2010) BDNF regulation under GFAP promoter provides engineered astrocytes as a new approach for long-term protection in Huntington's disease. Gene Ther., 17, 1294-1308.
24. Simmons, D.A., Belichenko, N.P.,Yang, T., Condon, C.,Monbureau, M., Shamloo, M., Jing, D., Massa, S.M. and Longo, F.M. (2013) A small molecule TrkB ligand reduces motor impairment and neuropathology in R6/2 and BACHD mouse models of Huntington's disease. J. Neurosci., 33, 18712-18727.
25. Brinkmann, V., Billich, A., Baumruker, T., Heining, P., Schmouder, R., Francis, G., Aradhye, S. and Burtin, P. (2010) Fingolimod (FTY720): discovery and development of an oral drug to treat multiple sclerosis. Nat. Rev. Drug Discov., 9, 883-897.
26. Deogracias, R., Yazdani, M., Dekkers, M.P.J., Guy, J., Ionescu, M.C.S., Vogt, K.E. and Barde, Y.-A. (2012) Fingolimod, a sphingosine-1 phosphate receptor modulator, increases BDNF levels and improves symptoms of a mouse model of Rett syndrome. Proc. Natl Acad. Sci., 109, 14230-14235.
27. Di Pardo, A., Amico, E., Favellato, M., Castrataro, R., Fucile, S., Squitieri, F. and Maglione, V. (2014) FTY720 (fingolimod) is a neuroprotective and disease-modifying agent in cellular and mouse models of Huntington disease. Hum. Mol. Genet., 23, 2251-2265.
28. Bigaud, M., Guerini, D., Billich, A., Bassilana, F. and Brinkmann, V. (2014) Second generation S1P pathway modulators: Research strategies and clinical developments. Biochim. Biophys. Acta - Mol. Cell Biol. Lipids, 1841, 745-758.
29. Choi, J.W., Gardell, S.E., Herr, D.R., Rivera, R., Lee, C.-W., Noguchi, K., Teo, S.T., Yung, Y.C., Lu, M., Kennedy, G. et al. (2011) FTY720 (fingolimod) efficacy in an animal model of multiple sclerosis requires astrocyte sphingosine 1-phosphate receptor 1 (S1P1) modulation. Proc. Natl Acad. Sci. USA, 108, 751-756.
30. Jung, C.G., Kim, H.J., Miron, V.E., Cook, S., Kennedy, T.E., Foster, C.A., Antel, J.P. and Soliven, B. (2007) Functional consequences of S1P receptor modulation in rat oligodendroglial lineage cells. Glia, 55, 1656-1667.
31. Noda, H., Takeuchi, H., Mizuno, T. and Suzumura, A. (2013) Fingolimod phosphate promotes the neuroprotective effects of microglia. J. Neuroimmunol., 256, 13-18.
32. Colombo, E., Di Dario, M., Capitolo, E., Chaabane, L., Newcombe, J., Martino, G. and Farina, C. (2014) Fingolimod may support neuroprotection via blockade of astrocyte nitric oxide. Ann. Neurol., 76, 325-337.
33. Yu, Z.-X., Li, S.-H., Evans, J., Pillarisetti, A., Li, H. and Li, X.-J. (2003) Mutant huntingtin causes context-dependent neurodegeneration in mice with Huntington's disease. J. Neurosci., 23, 2193-2202.
34. Stack, E.C., Kubilus, J.K.,Smith, K., Cormier, K., Del Signore, S.J., Guelin, E., Ryu, H., Hersch, S.M. and Ferrante, R.J. (2005) Chronology of behavioral symptoms and neuropathological sequela in R6/2 Huntington's disease transgenic mice. J. Comp. Neurol., 490, 354-370.
35. Faideau, M., Kim, J., Cormier, K., Gilmore, R., Welch, M., Auregan, G., Dufour, N., Guillermier, M., Brouillet, E., Hantraye, P. et al. (2010) In vivo expression of polyglutamine-expanded huntingtin by mouse striatal astrocytes impairs glutamate transport: A correlation with Huntington's disease subjects. Hum. Mol. Genet., 19, 3053-3067.
36. Giralt, A., Carretón, O., Lao-Peregrin, C., Martín, E.D. and Alberch, J. (2011) Conditional BDNF release under pathological conditions improves Huntington's disease pathology by delaying neuronal dysfunction. Mol. Neurodegener., 6, 71.
37. Hsiao, H.Y., Chen, Y.C., Chen, H.M., Tu, P.H. and Chern, Y. (2013) A critical role of astrocyte-mediated nuclear factor-κB-dependent inflammation in Huntington's disease. Hum. Mol. Genet., 22, 1826-1842.
38. Bradford, J., Shin, J.-Y., Roberts, M.,Wang, C.-E., Li, X.-J. and Li, S. (2009) Expression of mutant huntingtin in mouse brain astrocytes causes age-dependent neurological symptoms. Proc. Natl Acad. Sci. USA, 106, 22480-22485.
39. Bradford, J., Shin, J.-Y., Roberts, M.,Wang, C.-E., Sheng, G., Li, S. and Li, X.-J. (2010) Mutant huntingtin in glial cells exacerbates neurological symptoms of Huntington disease mice. J. Biol. Chem., 285, 10653-10661.
40. Rossi, S., Lo Giudice, T., De Chiara, V., Musella, A., Studer, V., Motta, C., Bernardi, G., Martino, G., Furlan, R., Martorana, A. et al. (2012) Oral fingolimod rescues the functional deficits of synapses in experimental autoimmune encephalomyelitis. Br. J. Pharmacol., 165, 861-869.
41. Asle-Rousta, M., Kolahdooz, Z., Oryan, S., Ahmadiani, A. and Dargahi, L. (2013) FTY720 (fingolimod) attenuates beta-amyloid peptide (Aß42)-induced impairment of spatial learning and memory in rats. J. Mol. Neurosci., 50, 524-532.
42. Fukumoto, K., Mizoguchi, H., Takeuchi, H., Horiuchi, H., Kawanokuchi, J., Jin, S., Mizuno, T. and Suzumura, A. (2014) Fingolimod increases brain-derived neurotrophic factor levels and ameliorates amyloid ß-induced memory impairment. Behav. Brain Res., 268, 88-93.
43. Spires, T.L., Grote, H.E., Garry, S., Cordery, P.M., Van Dellen, A., Blakemore, C. and Hannan, A.J. (2004) Dendritic spine pathology and deficits in experience-dependent dendritic plasticity in R6/1 Huntington's disease transgenic mice. Eur. J. Neurosci., 19, 2799-2807.
44. Nithianantharajah, J., Barkus, C., Murphy, M. and Hannan, A.J. (2008) Gene-environment interactions modulating cognitive function and molecular correlates of synaptic plasticity in Huntington's disease transgenic mice. Neurobiol Dis, 29, 490-504.
45. Torres-Peraza, J.F., Giralt, A., García-Martínez, J.M., Pedrosa, E., Canals, J.M. and Alberch, J. (2008) Disruption of striatal glutamatergic transmission induced by mutant huntingtin involves remodeling of both postsynaptic density and NMDA receptor signaling. Neurobiol. Dis., 29, 409-421.
46. Anglada-Huguet, M., Xifró, X., Giralt, A., Zamora-Moratalla, A., Martín, E.D. and Alberch, J. (2014) Prostaglandin E2 EP1 receptor antagonist improves motor deficits and rescues memory decline in R6/1 mouse model of Huntington's disease. Mol. Neurobiol., 49, 784-795.
47. Huxford, T., Huang, D.B., Malek, S. and Ghosh, G. (1998) The crystal structure of the IkappaBalpha/NF-kappaB complex revealsmechanisms of NF-kappaB inactivation. Cell, 95, 759-770.
48. Glass, C.K., Saijo, K.,Winner, B., Marchetto, M.C. and Gage, F. H. (2010) Mechanisms Underlying Inflammation in neurodegeneration. Cell, 140, 918-934.
49. Yirmiya, R. and Goshen, I. (2011) Immune modulation of learning, memory, neural plasticity and neurogenesis. Brain. Behav. Immun., 25, 181-213.
50. Tong, L., Prieto, G.A., Kramár, E.A., Smith, E.D., Cribbs, D.H., Lynch, G. and Cotman, C.W. (2012) Brain-derived neurotrophic factor-dependent synaptic plasticity is suppressed by interleukin-1ß via p38 mitogen-activated protein kinase. J. Neurosci., 32, 17714-17724.
51. Maqbool, A., Lattke, M.,Wirth, T. and Baumann, B. (2013) Sustained, neuron-specific IKK/NF-κB activation generates a selective neuroinflammatory response promoting local neurodegeneration with aging. Mol. Neurodegener., 8, 40.
52. Hait, N.C., Wise, L.E., Allegood, J.C., O'Brien, M., Avni, D., Reeves, T.M., Knapp, P.E., Lu, J., Luo, C., Miles, M.F. et al. (2014) Active, phosphorylated fingolimod inhibits histone deacetylases and facilitates fear extinction memory. Nat. Neurosci., 17, 971-980.
53. Choi, S. and Friedman,W.J. (2009) Inflammatory cytokines IL-1ß and TNF-a regulate p75NTR expression in CNS neurons and astrocytes by distinct cell-type-specific signalling mechanisms. ASN Neuro, 1.
54. Tully, T., Bourtchouladze, R., Scott, R. and Tallman, J. (2003) Targeting the CREB pathway for memory enhancers. Nat. Rev. Drug Discov., 2, 267-277.
55. Pierre, S.C., Häusler, J., Birod, K., Geisslinger, G. and Scholich, K. (2004) PAM mediates sustained inhibition of cAMP signaling by sphingosine-1-phosphate. EMBO J., 23, 3031-3040.
56. Healy, L.M., Sheridan, G.K., Pritchard, A.J., Rutkowska, A., Mullershausen, F. and Dev, K.K. (2013) Pathway specific modulation of S1P1 receptor signalling in rat and human astrocytes. Br. J. Pharmacol., 169, 1114-1129.
57. Yamashita, T., Tucker, K.L. and Barde, Y.A. (1999) Neurotrophin binding to the p75 receptor modulates Rho activity and axonal outgrowth. Neuron, 24, 585-593.
58. Lang, P., Gesbert, F., Delespine-Carmagnat, M., Stancou, R., Pouchelet, M. and Bertoglio, J. (1996) Protein kinase A phosphorylation of RhoA mediates the morphological and functional effects of cyclic AMP in cytotoxic lymphocytes. EMBO J., 15, 510-519.
59. Giralt, A., Saavedra, A., Alberch, J. and Pérez-Navarro, E. (2012) Cognitive dysfunction in Huntington's disease: humans, mouse models and molecular mechanisms. J. Huntington's Dis., 1, 155-173.
60. Heck, N., Betuing, S., Vanhoutte, P. and Caboche, J. (2012) A deconvolution method to improve automated 3D-analysis of dendritic spines: application to a mouse model of Huntington's disease. Brain Struct. Funct., 217, 421-434.
61. Murmu, R.P., Li,W., Holtmaat, A. and Li, J.-Y. (2013) Dendritic spine instability leads to progressive neocortical spine loss in a mouse model of Huntington's disease. J. Neurosci., 33, 12997-13009.
62. Fiala, J.C., Spacek, J. and Harris, K.M. (2002) Dendritic spine pathology: Cause or consequence of neurological disorders? Brain Res. Rev., 39, 29-54.
63. Goshen, I., Brodsky, M., Prakash, R.,Wallace, J., Gradinaru, V., Ramakrishnan, C. and Deisseroth, K. (2011) Dynamics of retrieval strategies for remote memories. Cell, 147, 678-689.
64. Chapman, T.R., Barrientos, R.M., Ahrendsen, J.T., Maier, S.F. and Patterson, S.L. (2010) Synaptic correlates of increased cognitive vulnerability with aging: peripheral immune challenge and aging interact to disrupt theta-burst late-phase long-term potentiation in hippocampal area CA1. J. Neurosci., 30, 7598-7603.
65. Chapman, T.R., Barrientos, R.M., Ahrendsen, J.T., Hoover, J.M., Maier, S.F. and Patterson, S.L. (2012) Aging and infection reduce expression of specific brain-derived neurotrophic factor mRNAs in hippocampus. Neurobiol. Aging, 33, 832.
66. Björkqvist, M., Wild, E.J., Thiele, J., Silvestroni, A., Andre, R., Lahiri, N., Raibon, E., Lee, R.V., Benn, C.L., Soulet, D. et al. (2008) A novel pathogenic pathway of immune activation detectable before clinical onset in Huntington's disease. J. Exp. Med., 205, 1869-1877.
67. Hsiao, H.-Y., Chiu, F.-L., Chen, C.-M., Wu, Y.-R., Chen, H.-M., Chen, Y.-C., Kuo, H.-C. and Chern, Y. (2014) Inhibition of soluble tumor necrosis factor is therapeutic in Huntington's disease. Hum. Mol. Genet., 23, 4328-4344.
68. Medeiros, R., Prediger, R.D.S., Passos, G.F., Pandolfo, P., Duarte, F.S., Franco, J.L., Dafre, A.L., Di Giunta, G., Figueiredo, C.P., Takahashi, R.N. et al. (2007) Connecting TNF-alpha signaling pathways to iNOS expression in a mouse model of Alzheimer's disease: relevance for the behavioral and synaptic deficits induced by amyloid beta protein. J. Neurosci., 27, 5394-5404.
69. Weberpals, M., Hermes, M., Hermann, S., Kummer, M.P., Terwel, D., Semmler, A., Berger, M., Schäfers, M. and Heneka, M. T. (2009) NOS2 gene deficiency protects from sepsis-induced long-term cognitive deficits. J. Neurosci., 29, 14177-14184.
70. Belarbi, K., Jopson, T., Tweedie, D., Arellano, C., Luo,W., Greig, N.H. and Rosi, S. (2012) TNF-a protein synthesis inhibitor restores neuronal function and reverses cognitive deficits induced by chronic neuroinflammation. J. Neuroinflammation, 9, 23.
71. Tancredi, V., D'Arcangelo, G., Grassi, F., Tarroni, P., Palmieri, G., Santoni, A. and Eusebi, F. (1992) Tumor necrosis factor alters synaptic transmission in rat hippocampal slices. Neurosci. Lett., 146, 176-178.
72. Albensi, B.C. and Mattson, M.P. (2000) Evidence for the involvement of TNF and NF-kappaB in hippocampal synaptic plasticity. Synapse, 35, 151-159.
73. Pineda, J.R., Canals, J.M., Bosch, M., Adell, A., Mengod, G., Artigas, F., Ernfors, P. and Alberch, J. (2005) Brain-derived neurotrophic factor modulates dopaminergic deficits in a transgenic mouse model of Huntington's disease. J Neurochem, 93, 1057-1068.
74. Plotkin, J.L., Day, M., Peterson, J.D., Xie, Z., Kress, G.J., Rafalovich, I., Kondapalli, J., Gertler, T.S., Flajolet, M., Greengard, P. et al. (2014) Impaired TrkB receptor signaling underlies corticostriatal dysfunction in Huntington's disease. Neuron, 83, 178-188.
75. Choi, S. and Friedman, W.J. (2014) Interleukin-1ß enhances neuronal vulnerability to proNGF-mediated apoptosis by increasing surface expression of p75NTR and sortillin. Neuroscience, 257, 11-19.
76. Álvarez, A., Cacabelos, R., Sanpedro, C., García-Fantini, M. and Aleixandre, M. (2007) Serum TNF-alpha levels are increased and correlate negatively with free IGF-I in Alzheimer disease. Neurobiol. Aging, 28, 533-536.
77. Hu, X.-Y., Zhang, H.-Y., Qin, S., Xu, H., Swaab, D.F. and Zhou, J.-N. (2002) Increased p75(NTR) expression in hippocampal neurons containing hyperphosphorylated tau in Alzheimer patients. Exp. Neurol., 178, 104-111.
78. Knowles, J.K., Simmons, D.A., Nguyen, T.V., Vander Griend, L., Xie, Y., Zhang, H., Yang, T., Pollak, J., Chang, T., Arancio, O. et al. (2013) A small molecule p75NTR ligand prevents cognitive deficits and neurite degeneration in an Alzheimer's mouse model. Neurobiol. Aging, 34, 2052-2063.
79. Giralt, A., Saavedra, A., Carretón, O., Arumí, H., Tyebji, S., Alberch, J. and Pérez-Navarro, E. (2013) PDE10 inhibition increases GluA1 and CREB phosphorylation and improves spatial and recognition memories in a Huntington's disease mouse model. Hippocampus, 23, 684-695.
80. Wang, C., Yang, X.-M., Zhuo, Y.-Y., Zhou, H., Lin, H.-B., Cheng, Y.-F., Xu, J.-P. and Zhang, H.-T. (2012) The phosphodiesterase-4 inhibitor rolipram reverses Aß-induced cognitive impairment and neuroinflammatory and apoptotic responses in rats. Int. J. Neuropsychopharmacol., 15, 749-766.
81. Nakayama, A.Y., Harms, M.B. and Luo, L. (2000) Small GTPases Rac and Rho in the maintenance of dendritic spines and branches in hippocampal pyramidal neurons. J. Neurosci., 20, 5329-5338.
82. Tashiro, A., Minden, A. and Yuste, R. (2000) Regulation of dendritic spine morphology by the rho family of small GTPases: antagonistic roles of Rac and Rho. Cereb. Cortex, 10, 927-938.
83. DerMardirossian, C. and Bokoch, G.M. (2005) GDIs: central regulatory molecules in Rho GTPase activation. Trends Cell Biol., 15, 356-363.
84. Kast, R.E. (2000) Tumor necrosis factor has positive and negative selfregulatory feedback cycles centered around cAMP. Int. J. Immunopharmacol., 22, 1001-1006.
85. Neumann, H., Schweigreiter, R., Yamashita, T., Rosenkranz, K., Wekerle, H. and Barde, Y.-A. (2002) Tumor necrosis factor inhibits neurite outgrowth and branching of hippocampal neurons by a rho-dependent mechanism. J. Neurosci., 22, 854-862.
86. Ricobaraza, A., Cuadrado-Tejedor, M., Marco, S., Pérez-Otaño, I. and García-Osta, A. (2012) Phenylbutyrate rescues dendritic spine loss associated with memory deficits in a mouse model of Alzheimer disease. Hippocampus, 22, 1040-1050.
87. Marco, S., Giralt, A., Petrovic, M.M., Pouladi, M.A., Martínez-Turrillas, R., Martínez-Hernández, J., Kaltenbach, L.S., Torres-Peraza, J., Graham, R.K.,Watanabe, M. et al. (2013) Suppressing aberrant GluN3A expression rescues synaptic and behavioral impairments in Huntington's disease models. Nat. Med., 19, 1030-1038.
88. Gratacos, E., Checa, N. and Alberch, J. (2001) Bone morphogenetic protein-2, but not bone morphogenetic protein-7, promotes dendritic growth and calbindin phenotype in cultured rat striatal neurons. Neuroscience, 104, 783-790.
89. Livak, K. and Schmittgen, T. (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2 (-Delta Delta C(T)) method. Methods, 25, 402-408.